ライフサイエンスコーパス: iron chelate

1 r iron acquisition from low-molecular-weight iron chelates.

2 ke from transferrin and low molecular weight iron chelates.

3 The iron chelating abilities of these molecules have been ch

4 eptides smaller than 5kDa were evaluated for iron chelating ability through measurements of iron solu

5 All the fractions demonstrated low iron chelating activity and did not inhibit oxidation in

6 eeds were analyzed for antioxidant activity, Iron chelating activity and total phenolic content.

7 In contrast, reducing power and iron chelating activity seemed to be caused by peptides.

8 activity (78% and 82%, respectively), while iron chelating activity was the highest in fractions A1

9 ical scavenging activity, reducing power and iron chelating activity.

10 ging assay showed 71.3% inhibition and 65.8% Iron chelating activity.

11 an seeds are good source of antioxidants and Iron chelating activity.

12 scavenging activity and possessed increased iron-chelating activity and reducing power.

13 elating defect; demonstrating production and iron-chelating activity for both siderophores.

14 Iron-chelating activity was higher in purified peptide f

15 contents were positively correlated with the iron-chelating activity.

16 eptides were purified and analysed for their iron-chelating activity.

17 rk contrast to this behavior, addition of an iron chelating agent (citrate) to the protein solution r

18 effect was augmented by desferroioxamine, an iron chelating agent.

19 evaluation both as a potential orally active iron-chelating agent and as a parenteral iron chelator.

20 rable with deferoxamine, a clinically useful iron-chelating agent.

21 red when choosing the appropriate dose of an iron-chelating agent.

22 Well-known as specific iron chelating agents produced by bacteria, it is shown

23 ric oxide and free-radical formation, use of iron chelating agents, the potential role of hypoxia-ind

24 is via the secretion of low-molecular-weight iron-chelating agents (siderophores).

25 These results demonstrate that iron-chelating agents such as PCIH may be of benefit in

26 AcnD activity was lost after incubation with iron-chelating agents, and no AcnD activity was observed

27 l treatments with conventional growth medium iron chelate and SPIONs (as iron source), indicated no s

28 rpose To synthesize two low-molecular-weight iron chelates and compare their T1 contrast effects with

29 nding is likely due to the 21-aminosteroid's iron-chelating and cell-permeating abilities, and sugges

30 tes on the function of FbpA as a carrier for iron chelates as well as "naked" or free iron as origina

31 levels by supplementation with a variety of iron chelates at >1 muM, including iron(III) dicitrate,

32 Hydroxyl radicals generated by the iron chelate attached at position 187 resulted in DNA st

33 and appearance of the high-spin signal from iron chelated by 6-OHDA oxidation products; (2) spectrop

34 vitamin B(12) (cyano-cobalamin [CN-Cbl]) and iron chelates by use of sequential active transport proc

35 The use of site-specifically tethered iron chelates can reveal protein-protein interactions, b

36 rption spectroscopy (AAS) was used to verify iron chelating capability of nanogels.

37 ation of iron (Fe)-transferrin generates new iron chelates capable of catalyzing hydroxyl radical (.O

38 es eliciting activities rely on their strong iron-chelating capacity.

39 The iron-chelating catechol siderophore vibriobactin of the

40 ne-di(o-hydroxyphenyl-acetic acid), or other iron-chelating compounds.

41 tants KP1344 (tonB) and RA1051 (exbBD) under iron-chelated conditions further support the roles of th

42 uced growth under static (limited aeration), iron-chelated conditions, while a yfe feo double mutant

43 mutant Escherichia coli strain, 1017, under iron-chelated conditions.

44 A. actinomycetemcomitans cells to grow under iron-chelated conditions.

45 harboring afeABCD promoted cell growth under iron-chelated conditions.

46 tion of both systems resulted in an in vitro iron-chelating defect; demonstrating production and iron

47 These properties of the novel multimodal iron-chelating drugs possessing neuroprotective/neuritog

48 d multifunctional, nontoxic, brain-permeable iron-chelating drugs, M30 and HLA20, possessing the N-pr

49 d liver iron, and from the availability of 3 iron-chelating drugs.

50 ify uptake mechanisms for Fe(3+), Fe(2+) and iron chelates (e.g. siderophore and haem iron complexes)

51 Using tethered iron chelate (Fe-BABE) derivatives of the enhancer-depen

52 The iron chelate FeBABE [iron (S)-1-(p-bromoacetamidobenzyl)

53 i siderophore receptor, FepA, that binds the iron chelate ferric enterobactin and colicins B and D.

54 insoluble ferric hydroxide and the mammalian iron chelates ferritin and transferrin.

55 occal TdTs facilitate utilization of iron or iron chelates from host-derived proteins, including tran

56 dramatically reduced by mimosine due to its iron-chelating function.

57 ds iron in a hexadentate fashion using a new iron-chelating gamma-amino acid.

58 t moderately higher concentrations, however, iron chelates generated similar contrast effects at T1-w

59 ygenases are involved in the biosynthesis of iron-chelating hydroxamate-containing siderophores that

60 h is subsequently formylated to generate the iron-chelating hydroxamates of the siderophore pyoverdin

61 Transport of iron chelates is accomplished by TonB-dependent transpor

62 ability to acquire siderophores and/or haem iron chelates is beneficial.

63 Specifically, we focused on the role of iron chelating ligands in promoting chemical oxidation o

64 ir inactivation results in growth defects in iron-chelated media, without affecting acinetobactin bio

65 derivative 1644, which was unable to grow in iron-chelated media.

66 ons in this gene abrogate growth of SAB11 on iron-chelated media.

67 bic conditions, and in iron-supplemented and iron-chelated medium.

68 yclodextrin (beta-CD) and ferrocene (Fc) and iron chelating moieties composed of deferoxamine (DFO) i

69 This work expands the repertoire of iron-chelating moieties in microbial siderophores.

70 ctive moiety of rasagiline (Azilect) and the iron-chelating moiety of VK28.

71 Small iron-chelating molecules called siderophores were select

72 paired (100- to 2500-fold) adsorption of the iron chelate more strongly.

73 e method is based on the reaction of NO with iron chelates of N-methylglucamine dithio-carbamate (MGD

74 The iron-chelating peptide vibriobactin of the pathogenic Vi

75 These results show that iron-chelating peptides are generated after chickpea pro

76 Iron-chelating peptides were isolated using immobilized

77 cavenging activity, higher on green tea, and iron chelating potential, higher on L. algarvense.

78 Tethered iron chelate probes attached to amino and carboxyl-termi

79 d this effect is fully related to its potent iron-chelating property in the organelle.

80 resulting in simultaneously secretion of the iron chelating protein lipocalin 2 (LCN2) and protons, w

81 The iron chelate reagent Fe-BABE was conjugated onto unique

82 an genital infection using the intracellular iron-chelating reagent deferoxamine mesylate (Desferal).

83 1 structure in a complex with the biliverdin-iron chelate show two major differences.

84 Pathogenic mycobacteria synthesize iron chelating siderophores named mycobactin and carboxy

85 endent transporters (TBDTs), which transport iron-chelating siderophores and vitamin B(12) across the

86 ococcus aureus, produce low-molecular-weight iron-chelating siderophores.

87 oteins form energized, gated pores that bind iron chelates (siderophores) and internalize them.

88 incorporates the common 2,3-dihydroxybenzoyl iron-chelating subunit, PB is novel in that it incorpora

89 clinical trials evaluating the usefulness of iron-chelating therapy in critical illness and sepsis.

90 icipated, of whom 216 (84.7%) were receiving iron-chelating therapy.

91 re receptors are components of high-affinity iron-chelate transport systems in gram-negative bacteria

92 atients with long-standing disease requiring iron-chelating treatment and a history of splenectomy ne

93 Iron efflux via an iron-chelating tricarboxylic acid cycle intermediate pro

94 rrier protein domains during assembly of the iron-chelating virulence factor, yersiniabactin of the p